Psyence Biomedical provides update on position in global ibogaine market

Psyence Biomedical (PBM) provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand. Recent signals from U.S. policymakers and global health authorities reflect increasing recognition of the need for structured, evidence-based evaluation of ibogaine, particularly in areas where existing treatment options remain limited. In anticipation of this shift, Psyence BioMed has spent the past year advancing a purpose-built platform designed to support ibogaine-based programs across development and potential commercialization. Through its investment in and collaboration with PsyLabs, the Company has established an integrated supply and GMP-compliant manufacturing platform spanning sourcing at origin, extraction, purification, and pharmaceutical production. As a key operational milestone, the Company confirms it currently holds standardized, stabilized, and GMP-compliant ibogaine doses in inventory. This supply is designed to support ongoing and future research initiatives, providing immediate access to pharmaceutical-grade material and helping to reduce delays associated with supply constraints.